argenx
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- argenx
- Target Recruit Count
- 40
- Registration Number
- NCT03334084
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- argenx
- Target Recruit Count
- 34
- Registration Number
- NCT03334058
- Locations
- ðŸ‡ðŸ‡º
University of Pécs Clinical Center , Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary
ðŸ‡ðŸ‡ºUniversity of Szeged Faculty of Medicine Albert Szent-Györgyi Medical Center Department of Dermatology and Allergology, Szeged, Hungary
🇮🇱HaEmek Medical center, Dermatology Department, 'Afula, Israel
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- argenx
- Target Recruit Count
- 38
- Registration Number
- NCT03102593
- Locations
- ðŸ‡ðŸ‡º
Gyula, Gyula, Hungary
🇦🇹Vienna, Vienna, Austria
🇫🇷Paris, Paris, France
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Phase 2
Completed
- Conditions
- Myasthenia Gravis
- Interventions
- Drug: PlaceboBiological: ARGX-113
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 24
- Registration Number
- NCT02965573
- Locations
- 🇺🇸
Investigator Site 19, Irvine, California, United States
🇺🇸Investigator Site 17, Los Angeles, California, United States
🇺🇸Investigator Site 16, Indianapolis, Indiana, United States
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- argenx
- Target Recruit Count
- 11
- Registration Number
- NCT02759250
- Locations
- 🇧🇪
UZG - Universitair Ziekenhuis Gent, Gent, Belgium
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- argenx
- Target Recruit Count
- 24
- Registration Number
- NCT02055066
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪Universitair Zieckenhuis Antwerpen, Antwerp, Belgium
© Copyright 2025. All Rights Reserved by MedPath